This website uses cookies to ensure that we give you the best experience and offer services that are relevant to you. If you close this banner, scroll down or click anywhere on this page, you are giving consent to cookies being used. If you want to know more about cookies or disable some or all of them please read the Privacy Policy.


Reporting of suspected drug adverse reactions

The spontaneous reporting of suspected drug adverse reactions represents an important source of information for pharmacovigilance activities, as it allows to detect potential safety signals about the use of all the drugs available on the market. Pharmacovigilance involves patients, prescribing doctors, healthcare professionals, pharmaceutical companies, institutions and universities; not only healthcare professionals can report suspected adverse reactions, but also citizens.


Every country has specific laws governing the reporting of adverse drug reactions, therefore if you experience adverse drug reactions with Ecupharma medicinal products authorised in a specific country, you are asked to report the suspected drug adverse reaction according to the local legislation or directly to Ecupharma (see below).

If you are taking an Ecupharma’s medicinal product authorised in Italy

To report a suspected adverse reaction occurring after the use of an Ecupharma’s medicinal product authorised in Italy, one of the following methods can be applied:

  1. Fill the dedicated report sheet available on the link and forward it by e-mail or fax to the Responsible for Pharmacovigilance of the competent Local Health Authority (ASL) to the addresses reported in the following web site:

  2. Online on the AIFA website (as healthcare professionals and citizens), report an adverse reaction (ADR):

  3. Reports can be forwarded directly to Ecupharma. To contact the Ecupharma pharmacovigilance team, please fill in the form down below 

  4. Alternatively, suspected adverse drug reactions can be reported to the Company by the following link: Segnalazioni di farmacovigilanza (
    You are invited to view the Privacy information by consenting to the processing of personal data, including any sensitive personal data, in accordance with General Data Protection Regulation (UE Regulation 679/2016). *


Fill in all fields in the form.

Fields with * are mandatory.

Inserisci il nome del farmaco da segnalare